Review article · 2023 · Open access
Artificial Intelligence for Drug Discovery: Are We There Yet?
The Annual Review of Pharmacology and Toxicology, 64(1), 527–550 · Published 22 September 2023 · DOI 10.1146/annurev-pharmtox-040323-040828
In brief
“Artificial Intelligence for Drug Discovery: Are We There Yet?” is a 2023 review article by Catrin Hasselgren and Tudor Ionel Oprea, published in The Annual Review of Pharmacology and Toxicology. OpenAlex counts 311 citations as of 22 November 2026, which puts it in the top 3% of works published in 2023 by citations. It is open access under a public domain licence: the full text is free to read at The Annual Review of Pharmacology and Toxicology.
- Citations
- 311
- Most cited in
- 2025 (137)
- Field-weighted impact
- 4.55
- References
- 176
- Authors
- 2
Abstract
Drug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal experiments. AI is transforming drug discovery, as indicated by increasing interest from investors, industrial and academic scientists, and legislators. Successful drug discovery requires optimizing properties related to pharmacodynamics, pharmacokinetics, and clinical outcomes. This review discusses the use of AI in the three pillars of drug discovery: diseases, targets, and therapeutic modalities, with a focus on small-molecule drugs. AI technologies, such as generative chemistry, machine learning, and multiproperty optimization, have enabled several compounds to enter clinical trials. The scientific community must carefully vet known information to address the reproducibility crisis. The full potential of AI in drug discovery can only be realized with sufficient ground truth and appropriate human intervention at later pipeline stages.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? The Annual Review of Pharmacology and Toxicology, 64(1), 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828
MLA 9
Hasselgren, Catrin, and Tudor Ionel Oprea. “Artificial Intelligence for Drug Discovery: Are We There Yet?” The Annual Review of Pharmacology and Toxicology, vol. 64, no. 1, 2023, pp. 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828.
Chicago
Hasselgren, Catrin and Tudor Ionel Oprea. 2023. “Artificial Intelligence for Drug Discovery: Are We There Yet?” The Annual Review of Pharmacology and Toxicology 64 (1): 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828.
Harvard
Hasselgren, C. and Oprea, T. I. (2023) ‘Artificial Intelligence for Drug Discovery: Are We There Yet?’, The Annual Review of Pharmacology and Toxicology, 64(1), pp. 527–550. doi:10.1146/annurev-pharmtox-040323-040828.
IEEE
C. Hasselgren and T. I. Oprea, “Artificial Intelligence for Drug Discovery: Are We There Yet?,” The Annual Review of Pharmacology and Toxicology, vol. 64, no. 1, pp. 527–550, 2023, doi: 10.1146/annurev-pharmtox-040323-040828.
BibTeX
@article{hasselgren2023artificial,
title = {{Artificial Intelligence for Drug Discovery: Are We There Yet?}},
author = {Hasselgren, Catrin and Oprea, Tudor Ionel},
journal = {The Annual Review of Pharmacology and Toxicology},
year = {2023},
volume = {64},
number = {1},
pages = {527--550},
doi = {10.1146/annurev-pharmtox-040323-040828},
url = {https://doi.org/10.1146/annurev-pharmtox-040323-040828}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 5 | |
| 2024 | 68 | |
| 2025 | 137 | |
| 2026 | 101 |
Its field-weighted citation impact is 4.55: it has been cited 4.55 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- artificial intelligence in drug discovery
- generative chemistry
- machine learning
- small molecule drugs
- therapeutic target
- therapeutic modalities
- replication crisis
- clinical trial candidates
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? The Annual Review of Pharmacology and Toxicology, 64(1), 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828
How many times has this paper been cited?
311 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Annual Review of Pharmacology and Toxicology: sign in and open the PDF from this page.
Who wrote this paper?
Catrin Hasselgren, Tudor Ionel Oprea.
What is the DOI of this paper?
10.1146/annurev-pharmtox-040323-040828, permanently at https://doi.org/10.1146/annurev-pharmtox-040323-040828. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.